Barclays PLC Has $147,000 Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Barclays PLC increased its stake in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 301.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,944 shares of the company’s stock after purchasing an additional 22,489 shares during the quarter. Barclays PLC’s holdings in Lifecore Biomedical were worth $147,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new stake in shares of Lifecore Biomedical during the second quarter worth $56,000. Creative Planning acquired a new stake in shares of Lifecore Biomedical during the 3rd quarter valued at $69,000. Public Employees Retirement System of Ohio bought a new stake in Lifecore Biomedical during the 3rd quarter worth $119,000. Rhumbline Advisers increased its holdings in Lifecore Biomedical by 1,668.5% in the 2nd quarter. Rhumbline Advisers now owns 26,899 shares of the company’s stock worth $138,000 after purchasing an additional 25,378 shares in the last quarter. Finally, Jane Street Group LLC raised its position in Lifecore Biomedical by 101.7% in the third quarter. Jane Street Group LLC now owns 36,246 shares of the company’s stock valued at $179,000 after purchasing an additional 18,277 shares during the last quarter. Institutional investors own 83.36% of the company’s stock.

Wall Street Analyst Weigh In

LFCR has been the topic of several research reports. Stephens restated an “equal weight” rating and set a $6.00 price target on shares of Lifecore Biomedical in a report on Friday, January 3rd. Craig Hallum lifted their target price on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 22nd.

Lifecore Biomedical Stock Down 14.0 %

Shares of NASDAQ:LFCR opened at $5.91 on Wednesday. The firm has a market cap of $217.65 million, a P/E ratio of 73.88 and a beta of 0.98. Lifecore Biomedical, Inc. has a 12-month low of $3.68 and a 12-month high of $8.90. The business has a fifty day simple moving average of $7.05 and a 200 day simple moving average of $5.82. The company has a quick ratio of 0.80, a current ratio of 1.83 and a debt-to-equity ratio of 12.90.

Lifecore Biomedical (NASDAQ:LFCR) last issued its quarterly earnings data on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%. Analysts predict that Lifecore Biomedical, Inc. will post -0.99 earnings per share for the current year.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.